MRVI · Maravai Lifesciences Holdings, Inc.
$6.25
-0.17 (-2.57%)
At close · Aug 6
Earnings today
Market Cap
$1.65B
Shares
258.19M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.41
Open$6.43
Day$6.33–6.52
52W$1.99–7.44
Avg vol 30d2.9M
Short int9.3M · 3.6% float · 3.0d
Short vol54%
Last earningsAug 6, 2026
DataNov 2020–Aug 2026
Filing10-Q · May 8
Up next
Earnings call today
Aug 6, 2026
Today
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+57%
above
Price vs 50-day avg
+9%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
81%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+105%
trailing
YTD return
+97%
this year
Relative strength
+94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
35 of 158 funds reported for Jun 30 · net +437.6K sh shares · +3 new
Insider flow
Distributing
Net -$254.0K over 90 days · 100% sells
Short interest
Rising
3.59% of float · ▲ +5.2% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
158 holders — mid 3-yr range
Squeeze score
73
high risk · 0–100
Fundamentals
Revenue growth
−28%
Y/Y
Gross margin
18%
contracting
EPS growth
+14%
Y/Y
Free cash flow
$-70.7M
Balance sheet
$74.9M
net debt
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Revenue
· full year 2026
Initiated
$205M – $215M
prior FY $185.74M
midpoint +13.1% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+57%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
81%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
35 of 158 funds reported for Jun 30 · net +437.6K sh shares · +3 new
Insider flow
Distributing
Net -$254.0K over 90 days · 100% sells
Short interest
Rising
3.59% of float · ▲ +5.2% MoM · 3.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
158 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $6 · 81%
52-wk high $7
vs 200-day avg +57%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow | $4.2M | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MRVI
this stock
Maravai Lifesciences Holdings, Inc.
|
$1.65B | +97.2% | -67.3% | — | 3.6% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MRVI | -2.7% | +11.3% | +105.5% | -2.4% | +97.2% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -8.3% | +8.0% | +94.2% | -5.5% | +84.3% |
Key facts
CIK
1823239
CUSIP
56600D107
13F (30d)
29 filings
29 filers
Visit website
Investor relations